Spots Global Cancer Trial Database for Phase 2 Study to Evaluate the Oral Combination of Ixazomib (MLN9708) With Cyclophosphamide and Dexamethasone in Patients With Newly Diagnosed or Relapsed and/or Refractory Multiple Myeloma

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: Phase 2 Study to Evaluate the Oral Combination of Ixazomib (MLN9708) With Cyclophosphamide and Dexamethasone in Patients With Newly Diagnosed or Relapsed and/or Refractory Multiple Myeloma

Official Title: An Open-Label, Phase 2 Study to Evaluate the Oral Combination of Ixazomib (MLN9708) With Cyclophosphamide and Dexamethasone in Patients With Newly Diagnosed or Relapsed and/or Refractory Multiple Myeloma Requiring Systemic Treatment

Study ID: NCT02046070

Conditions

Multiple Myeloma

Interventions

Cyclophosphamide

Ixazomib

Dexamethasone

Study Description

Brief Summary: This is a phase 2, multicenter, open-label study in patients with Newly Diagnosed Multiple Myeloma (NDMM) who have not received prior systemic treatment for multiple myeloma (MM) and who are ineligible for high-dose therapy (HDT)-stem cell transplantation (SCT) due to age (ie, ≥ 65 years) or comorbid disease(s) or with Relapsed and/or Refractory Multiple Myeloma (RRMM).

Detailed Description: The investigational drug being tested in this study is called MLN9708 also known as Ixazomib. This study will look at disease response rates and safety in people who take ixazomib in addition to cyclophosphamide and dexamethasone. NDMM participants will be randomly assigned (by chance, like flipping a coin) to one of two treatment groups and RRMM participants will be assigned to a third group: * NDMM - ixazomib (MLN9708) 4.0 mg + cyclophosphamide 300 mg/m\^2 + dexamethasone 40 mg * NDMM - ixazomib (MLN9708) 4.0 mg + cyclophosphamide 400 mg/m\^2 + dexamethasone 40 mg * RRMM - ixazomib (MLN9708) 4.0 mg + cyclophosphamide 300 mg/m\^2 + dexamethasone 40 mg The study enrolled 148 participants. This multi-centre trial will be conducted in the United States, European Union, and Australia.